Brief: X4 Pharmaceuticals Full Enrollment On Track For 3Q Or 4Q 2025 And Top-Line Data In 2H 2026
01/05/2025 11:43
May 1 (Reuters) - X4 Pharmaceuticals Inc XFOR.O: X4 PHARMACEUTICALS: FULL ENROLLMENT ON TRACK FOR 3Q OR 4Q 2025 AND TOP-LINE DATA IN 2H 2026 Source text: [ID:n0001628280-25-021304] Further company coverage: XFOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule